Eyeworld Daily News

29 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3 by Vanessa Caceres EyeWorld Contributing Writer I t is the goal of the ASCRS Foundation's Industry Relations Committee to directly involve corporate allies in the founda- tion's humanitarian and edu- cation work. By helping to advance the foundation's mission, industry can become a direct partner in an ongoing joint effort—one that the ASCRS leadership feels is important to recognize and celebrate. At the ASCRS•ASOA Symposium & Congress, all industry partners are invited to take part in a private, donors-only reception with the ASCRS Executive Committee and Governing Board. The reception serves as an opportunity to discuss future collaboration, as well as to make suggestions or voice concerns with those who shape the society's direction. Here are some of the many projects underway by the ASCRS Foundation: U.S.-based • The ASCRS Foundation's Oper- ation Sight charitable cataract surgery program matches needy American patients with volunteer ASCRS surgeons in their own com- munities. Four hundred surgeries have been performed during the program's first 18 months. • Research Grants. For the past 14 years, the ASCRS Foundation has provided $50,000 in seed funding to advance studies conducted by young physicians. • Resident Excellence Awards. The ASCRS Foundation works to accelerate the education of ophthalmology's next generation by providing travel stipends and complimentary hotel accommo- dations and registration for the ASCRS•ASOA Symposium & Con- gress to 10 outstanding residents and fellows each year. International • Approximately 19,000 patients per year are treated at the founda- tion's Robert Sinskey Eye Institute in Addis Ababa, Ethiopia. • The ASCRS Foundation sup- ports rural cataract outreach and physician education in Ethiopia through a partnership with the Himalayan Cataract Project. • Through a partnership with the Moran Eye Center (Salt Lake City), the ASCRS Foundation co-spon- sors a summer cataract surgery outreach effort to a country in the developing world. Two hundred cataract surgeries are performed during the 1-week mission. • The ASCRS Foundation is work- ing with DigiSight Technologies (San Francisco) on the launch of a cloud-based telemedicine pilot program in Nepal. EW ASCRS Foundation partners with industry and eyecare leaders to provide help around the globe

• Cover